BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 55 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $198 | 0.0% | 200,000 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $198 | -3.9% | 200,000 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $206 | +3.5% | 200,000 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $199 | -99.9% | 200,000 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $199,000 | +0.5% | 200,000 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $198,000 | -99.5% | 200,000 | -50.0% | 0.00% | -99.3% |
Q1 2022 | $40,316,000 | +91.4% | 400,000 | +100.0% | 0.15% | +125.8% |
Q4 2021 | $21,062,000 | +20348.5% | 200,000 | +100.0% | 0.07% | – |
Q3 2021 | $103,000 | -50.5% | 100,000 | -50.0% | 0.00% | – |
Q2 2021 | $208,000 | -49.3% | 200,000 | -50.0% | 0.00% | -100.0% |
Q1 2021 | $410,000 | -4.7% | 400,000 | 0.0% | 0.00% | – |
Q4 2020 | $430,000 | +105.7% | 400,000 | +100.0% | 0.00% | -100.0% |
Q3 2020 | $209,000 | -57.5% | 200,000 | -50.0% | 0.00% | -50.0% |
Q2 2020 | $492,000 | +16.0% | 400,000 | 0.0% | 0.00% | -33.3% |
Q4 2019 | $424,000 | – | 400,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 23,984,000 | $24,566,321 | 1.87% |
SSI INVESTMENT MANAGEMENT LLC | 14,019,000 | $14,383,199 | 1.01% |
PFM Health Sciences, LP | 15,000,000 | $15,427,185 | 0.68% |
Sonora Investment Management Group, LLC | 6,380,000 | $6,460,377 | 0.56% |
ADVENT CAPITAL MANAGEMENT /DE/ | 24,638,000 | $25,339,666 | 0.48% |
Lombard Odier Asset Management (Europe) Ltd | 9,000,000 | $9,099,180 | 0.45% |
RWC Asset Management LLP | 11,700,000 | $12,018,591 | 0.37% |
MACKAY SHIELDS LLC | 10,450,000 | $10,721,491 | 0.29% |
PALISADE CAPITAL MANAGEMENT, LP | 10,093,000 | $10,326,148 | 0.28% |
Nicholas Investment Partners, LP | 2,940,000 | $3,016,378 | 0.23% |